CHARGED ALPHA
Stock Analysis
Stock Library / NRIX
NRIX Unclassified Latest YouTube: Q2 FY2026

NRIX

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

NRIX Stock: Nurix Tripled After a $700M Roche Deal — Is the Good News Already Priced In?

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q2 FY2026
Podcast available
Yes
Current price
$23.12
+0.50 (+2.21%)
Trailing / Forward P/E
Forward: -10.45x
Market cap / Volume
Volume:
Revenue / Earnings Growth
-79.5%
Earnings: —
Margins
-1041.7% op
Gross: 0.0% · Net: 0.0%
Balance sheet
6.34x current
Debt / Equity: 14.4
52-week range / Beta
$8.19 - $25.08
Beta: 1.80
Analyst target
$32.50
Upside: 40.6%
Cash / shareholder return
-6.89% FCF yield
Dividend yield: —

Company context

Industry: Biotechnology
Country: United States
Employees:
Price to book: 5.95x
Return on equity: -80.3%
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Price chart

Market context for NRIX

Competitive view

NRIX vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

NRIX latest YouTube video thumbnail YouTube
NRIX
NRIX
Latest video
Q2 FY2026
Growth profile looks mature or currently muted, which can cap multiple expansion unless execution improves.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Expect a more volatile ride than the market average; that can amplify upside, but drawdowns can come fast too.
ADBE latest YouTube video thumbnail YouTube
ADBE
ADBE
Latest video
Q2 FY2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Abbott Laboratories latest YouTube video thumbnail YouTube
Abbott Laboratories
ABT
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
NRIX
$2.39B
NRIX
ADBE
$94.31B
ADBE
ABT
$175.37B
Abbott Laboratories
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
NRIX
NRIX
ADBE
13.6x
ADBE
ABT
28.2x
Abbott Laboratories
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
NRIX
-10.4x
NRIX
ADBE
8.6x
ADBE
ABT
16.6x
Abbott Laboratories
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
NRIX
-79.5%
NRIX
ADBE
12.7%
ADBE
ABT
7.8%
Abbott Laboratories
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
NRIX
NRIX
ADBE
7.9%
ADBE
ABT
-19.7%
Abbott Laboratories
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
NRIX
-1041.7%
NRIX
ADBE
35.3%
ADBE
ABT
13.5%
Abbott Laboratories
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
NRIX
0.0%
NRIX
ADBE
89.4%
ADBE
ABT
56.5%
Abbott Laboratories
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
NRIX
0.0%
NRIX
ADBE
28.7%
ADBE
ABT
13.9%
Abbott Laboratories
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
NRIX
-80.3%
NRIX
ADBE
63.0%
ADBE
ABT
12.3%
Abbott Laboratories
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
NRIX
-6.9%
NRIX
ADBE
9.8%
ADBE
ABT
3.6%
Abbott Laboratories
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
NRIX
14.44x
NRIX
ADBE
61.44x
ADBE
ABT
64.77x
Abbott Laboratories
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
NRIX
6.34x
NRIX
ADBE
0.75x
ADBE
ABT
1.39x
Abbott Laboratories
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
NRIX
1.80
NRIX
ADBE
1.43
ADBE
ABT
0.61
Abbott Laboratories
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
NRIX
NRIX
ADBE
ADBE
ABT
2.8%
Abbott Laboratories
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
NRIX
40.6%
NRIX
ADBE
14.8%
ADBE
ABT
15.8%
Abbott Laboratories

Related research

Non-quarter videos featuring NRIX

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-10

NRIX: Nurix tripled after a $700M Roche deal — is the good news priced in? #Shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

Episode timeline

Episode archive for NRIX

Each row is one earnings episode with every verified platform link available.

Q2 FY2026
Episode live
Published youtube podcast complete
NRIX Stock: Nurix Tripled After a $700M Roche Deal — Is the Good News Already Priced In?
Quarterly earnings-analysis entry for NRIX. Use the links on the right to open the video or podcast episode.